Entrada Therapeutics Inc (TRDA)
$7.08
$-0.22
(-3.01%)
As on 03-Sep-2026 15:39EDT
Market cap
$273 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4
-
Face value
--
-
Shares outstanding
38,936,669
5 Years Aggregate
CFO
$-41.22 Mln
EBITDA
$-183.75 Mln
Net Profit
$-175.24 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
| -31.1 | 4.3 | 6.6 | 31.6 | -22.8 | -- | -- |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
| -40.5 | 14.5 | 11.6 | -21.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Entrada Therapeutics Inc (TRDA)
|
7.1 | 272.6 | 4.7 | -165.8 | -3,520.3 | -61.5 | -- | 1.2 |
| 86.0 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 73.5 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 368.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.0 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's... Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Read more
-
CEO & Director
Mr. Dipal Doshi
-
CEO & Director
Mr. Dipal Doshi
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Entrada Therapeutics Inc (TRDA)
What is the current share price of Entrada Therapeutics Inc (TRDA) Today?
The share price of Entrada Therapeutics Inc (TRDA) is $7.08 (NASDAQ) as of 03-Sep-2026 15:39 EDT. Entrada Therapeutics Inc (TRDA) has given a return of -22.84% in the last 3 years.
What is the current PB & PE ratio of Entrada Therapeutics Inc (TRDA)?
Since, TTM earnings of Entrada Therapeutics Inc (TRDA) is negative, P/E ratio is not available.
The P/B ratio of Entrada Therapeutics Inc (TRDA) is 1.17 times as on 28-Aug-2026, a 77 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.96 |
1.39 |
2024 |
11.34 |
1.74 |
2023 |
-75.32 |
2.08 |
2022 |
-4.85 |
1.99 |
2021 |
-7.10 |
1.19 |
What is the 52 Week High and Low of Entrada Therapeutics Inc (TRDA)?
The 52-week high and low of Entrada Therapeutics Inc (TRDA) are Rs 16.45 and Rs 5.02 as of 04-Sep-2026.
What is the market cap of Entrada Therapeutics Inc (TRDA)?
Entrada Therapeutics Inc (TRDA) has a market capitalisation of $ 273 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Entrada Therapeutics Inc (TRDA)?
Before investing in Entrada Therapeutics Inc (TRDA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.